市場調查報告書
商品編碼
1403470
2030 年精準診斷市場預測:按類型、應用程式、最終用戶和地區分類的全球分析Precision Diagnostics Market Forecasts to 2030 - Global Analysis By Type (Direct to Consumer Tests, Esoteric Tests, Genetic Tests and Other Types), Application, End User and By Geography |
根據Stratistics MRC預測,2023年全球精準診斷市場規模將達793億美元,預計2030年將達到2,057億美元,預測期內複合年成長率為14.6%。
改進診斷技術以實現高精度和客製化醫療測試的市場被稱為精準診斷市場。精準診斷涉及使用蛋白質體學、基因組學和分子診斷等先進技術對患者樣本進行分子分析。該技術可以精確識別與特定疾病相關的基因突變、生物標記和其他分子指標。
根據世界衛生組織 (WHO) 的數據,2021 年 5 月,全球有 163,312,429 人受到 COVID-19 的影響。
患者和醫療保健專業人員越來越意識到準確的診斷可以對治療結果產生改變遊戲規則的影響。越來越多的人意識到其好處,包括早期發現疾病、客製化治療方法和更好的患者治療效果的潛力。此外,越來越多的複雜患者正在尋求尖端的診斷工具,以在分子層面上深入了解他們的健康狀況。
實施先進技術需要對專業機械、基礎設施和熟練員工進行大量前期投資。例子包括次世代定序和分子分析。這些高昂的初期成本為醫療機構和診斷實驗室帶來了財務挑戰,並可能限制患者獲得某些診斷服務。然而,財務負擔更大,因為它不僅僅是購買技術,還包括針對醫療專業人員的全面培訓課程。
癌症、心血管疾病和神經系統疾病等疾病的全球負擔日益增加,對準確、及時的診斷工具的需求日益增加。透過精確診斷,包括尖端分子和個體化醫療。此外,由於這些疾病通常需要專門治療,準確而徹底的診斷對於成功介入和改善患者預後至關重要。
精確診斷需要收集和分析高度敏感的患者資訊,包括遺傳和分子資料,因此確保穩健的資料保護措施極為重要。患者和醫療保健提供者擔心其個人健康資訊可能被濫用、資料外洩和詐欺的存取。然而,解決這些問題需要嚴格遵守 GDPR 和 HIPAA 等資料保護法,並且需要在網路安全基礎設施上投入大量資金。
這次疫情凸顯了快速準確診斷的重要性,但非緊急診斷程序的延遲以及將資源轉移到 COVID-19 檢測上導致了混亂。該行業對分子診斷(尤其是基於 PCR 的檢測)的需求激增,但供應鏈中斷和醫院基礎設施負擔過重困擾著該行業。傳統的診斷環境也受到了遠端醫療和遠距離診斷重點轉移的影響。
隨著精準醫療的普及,基因檢測領域擁有最大的市場佔有率。對分子譜分析和次世代定序等基因檢測的需求正在迅速增加。這些測試可以充分識別個體的遺傳組成,從而檢測特定的遺傳差異、對疾病的易感性以及可能的治療反應。此外,遺傳疾病發生率的增加和個體化醫療保健意識的增強也推動了基因檢測在疾病診斷、風險評估和治療計劃中的應用。
隨著分子測試、液體活體組織切片和基因組分析使識別與各種癌症類型相關的特定遺傳變化和生物標記成為可能,腫瘤學領域正在迅速擴展。這種精確度使腫瘤學家能夠根據每位患者的腫瘤特異性基因譜量身定做治療計劃,從而最佳化治療結果。全球癌症盛行率的不斷增加以及對其分子基礎的了解不斷加深,增加了對腫瘤學準確診斷技術的需求。
由於癌症和心血管疾病等慢性病盛行率的上升增加了對先進和準確診斷工具的需求,預計亞太地區將在預測期內佔據最大的市場佔有率。該地區的中產階級人口不斷成長,醫療保健專業知識不斷提高,特別注重預防性護理。此外,精準診斷的理念是提供量身定做的、有針對性的干涉措施,以改善患者的治療結果,這也符合醫療保健領域的這項運動。
由於科技的快速進步和醫療保健服務的不斷擴大,亞太地區正在經歷盈利成長。中國、日本和印度等國家在研發、基礎設施和醫療保健方面投入巨資,為引進尖端診斷技術提供了有利的環境。亞太地區持續優先開拓醫療基礎設施、投資研發和創新、經歷向精準醫療的範式轉變,使其成為支撐全球精準診斷市場成長和擴張的主要力量。會的。
According to Stratistics MRC, the Global Precision Diagnostics Market is accounted for $79.3 billion in 2023 and is expected to reach $205.7 billion by 2030 growing at a CAGR of 14.6% during the forecast period. The market for improved diagnostic technologies that enable very precise and customized medical testing is known as the "precision diagnostics market." Precision diagnostics entails the molecular analysis of patient samples using advanced methods, including proteomics, genomics, and molecular diagnostics. With this method, genetic variants, biomarkers, and other molecular indicators linked to certain diseases can be precisely identified.
According to the World Health Organization (WHO), in May 2021, 163,312,429 people worldwide were affected by COVID-19.
Patients and healthcare professionals' awareness of the revolutionary effect accurate diagnosis can have on treatment results is growing. An increasing number of people are becoming aware of the benefits of early disease detection, customized treatment regimens, and the possibility of better patient outcomes. Additionally, more and more sophisticated patients are asking for access to state-of-the-art diagnostic tools that can offer an in-depth understanding of their molecular health.
Advanced technology adoption requires large upfront investments in specialized machinery, infrastructure, and skilled employees. Some instances of these are next-generation sequencing and molecular profiling. These higher initial costs might pose an economic challenge for medical facilities, and diagnostic labs and potentially restrict patient access to specific precision diagnostic services. However, the financial burden is further increased by the fact that the expenses extend beyond the purchase of technology and involve thorough training courses for medical professionals.
Accurate and timely diagnostic tools are becoming more and more necessary due to the rising worldwide burden of diseases like cancer, cardiovascular diseases, and neurological disorders. The identification of certain genetic mutations, biomarkers, and molecular signatures associated with a range of chronic conditions is made possible by precision diagnostics, which includes cutting-edge molecular technology and customized medicine techniques. Additionally, accurate and thorough diagnoses are essential for successful intervention and better patient outcomes since these illnesses often require specialized therapies.
Ensuring strong data protection measures is crucial because precision diagnostics requires the collection and analysis of extremely sensitive patient information, including genetic and molecular data. Patients and healthcare providers are concerned about the possibility of misuse, data breaches, and unauthorized access to personal health information. However, strict adherence to data protection laws, such as GDPR and HIPAA, is necessary to address these issues, necessitating substantial expenditures in cybersecurity infrastructure.
While the pandemic emphasized the significance of rapid and accurate diagnosis, delays in non-urgent diagnostic procedures and the redirection of resources toward COVID-19 testing caused disruptions. Demand for molecular diagnostics, especially PCR-based tests, surged in the industry, but supply chain disruptions and overloaded hospital infrastructures posed problems. Traditional diagnostic settings were also impacted by a shift in emphasis toward telemedicine and remote diagnostics.
With the growing popularity of precision medicine, the genetic testing sector held the largest market share. Demand for genetic tests, such as molecular profiling and next-generation sequencing, is rapidly rising. An individual's genetic composition can be fully recognized by these tests, which can detect certain genetic differences, illness susceptibility, and possible treatment reactions. Additionally, the use of genetic tests for illness diagnosis, risk assessment, and treatment planning is being driven by the rising frequency of genetic illnesses and the increasing awareness of individualized healthcare.
Because molecular testing, liquid biopsies, and genomic profiling have made it possible to identify particular genetic changes and biomarkers linked to various cancer types, the oncology sector is expanding rapidly. With this level of accuracy, oncologists can optimize therapeutic outcomes by customizing treatment plans based on each patient's tumor's unique genetic profile. Accurate diagnostic techniques for oncology are in greater demand due to the rising global prevalence of cancer and our growing understanding of its molecular basis.
Because the demand for sophisticated and accurate diagnostic tools has increased due to the rising prevalence of chronic diseases, including cancer and cardiovascular disorders, the Asia-Pacific region is anticipated to hold the largest share of the market over the forecasted period. In addition, the area is experiencing a rise in the middle-class population and healthcare expertise, with a particular emphasis on preventive healthcare practices. Moreover, the precision diagnostic tenets of tailored and targeted interventions for better patient outcomes are in accordance with this movement in healthcare perspectives.
The Asia-Pacific region is growing profitably as a result of the rapid advancement in technology and the growing availability of healthcare services. Nations like China, Japan, and India have invested large investments in R&D, infrastructure, and healthcare, providing a climate that is favorable to the adoption of cutting-edge diagnostic technology. The Asia Pacific region will definitely be a major force behind the growth and expansion of the precision diagnostics market on a global scale as it continues to prioritize the development of healthcare infrastructure, invest in research and innovation, and experience a paradigm shift towards precision medicine.
Some of the key players in Precision Diagnostics market include Abbott, Bayer AG, Koninklijke Philips N.V., Lantheus Medical Imaging, Inc., Novartis AG, QIAGEN, Quest Diagnostics Incorporated, Sanofi, Siemens Healthineers AG and Swiss Precision Diagnostics GmbH.
In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform.
In September 2023, Abbott signs definitive agreement to acquire Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. As part of the acquisition, Abbott will use Bigfoot Unity with its FreeStyle Libre technology, which uses a customer smartphone app connected to a cloud-based online portal.
In May 2023, Bayer has secured a long-term structured renewable energy credit purchase agreement with Cat Creek Energy that will generate 1.4 terawatt-hours of clean electricity annually, equivalent to the energy consumption of 150,000 households.